Divi’s Laboratories (DIVISLAB) Q3 25/26 earnings summary

Executive summary

• Maintained stable operational performance in Q3 FY26, with strong supply reliability and process efficiencies across generics and custom synthesis segments.

• Healthy volume growth in select emerging products despite competitive pricing pressures in generics.

• Advanced multiple custom synthesis projects, with several nearing commercial volumes in the next year.

• Expanded peptide chemistry capabilities, supporting customer programs across all clinical phases.

• Consolidated total income for Q3 FY26 was ₹2,692 crores, up from ₹2,401 crores in Q3 FY25; nine-month total income reached ₹8,081 crores, up from ₹7,041 crores year-over-year.

Financial highlights

• Q3 FY26 consolidated total income: INR 2,692 crores (up from INR 2,401 crores YoY); nine-month total income: INR 8,081 crores (vs. INR 7,041 crores YoY).

• Profit before exceptional item and tax: INR 854 crores (vs. INR 726 crores YoY); after exceptional item, profit before tax: INR 780 crores.

• Profit after tax: INR 583 crores, broadly in line with INR 589 crores YoY; nine-month PAT was INR 1,817 crores, up from INR 1,529 crores.

• Material consumption reduced to 36.3% of sales revenue (from 39.8% YoY).

• Forex gains for Q3 FY26 were INR 19 crores consolidated and INR 18 crores standalone.

Outlook and guidance

• Operating environment for next six months expected to remain stable in raw material pricing and availability.

• Double-digit growth trajectory expected to continue, with no major disruptions anticipated from product lifecycle changes.

• Commercialization of three dedicated custom synthesis projects expected in Q3-Q4 of calendar year 2027, subject to regulatory approvals.

• Management continues to monitor the finalization of new labour codes and will adjust for any further impacts as regulations are clarified.